204 related articles for article (PubMed ID: 23528371)
21. Current treatment of peripheral T-cell lymphoma.
Horwitz SM; Coiffier B; Hsi ED; Pro B
Clin Adv Hematol Oncol; 2011 Aug; 9(8 Suppl 16):1-15. PubMed ID: 22361915
[TBL] [Abstract][Full Text] [Related]
22. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
23. Biomarker-driven management strategies for peripheral T cell lymphoma.
Mulvey E; Ruan J
J Hematol Oncol; 2020 May; 13(1):59. PubMed ID: 32448357
[TBL] [Abstract][Full Text] [Related]
24. High-dose therapy and stem cell transplantation.
Zinzani PL
Semin Hematol; 2010 Apr; 47 Suppl 1():S15-7. PubMed ID: 20359581
[TBL] [Abstract][Full Text] [Related]
25. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
26. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
[TBL] [Abstract][Full Text] [Related]
27. Emerging therapies in relapsed and refractory peripheral T-cell lymphoma.
Bachow SH; O'Connor OA
Clin Adv Hematol Oncol; 2015 Dec; 13(12):837-46. PubMed ID: 27058850
[TBL] [Abstract][Full Text] [Related]
28. Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials.
Ma H; Cheng B; Falchi L; Marchi E; Sawas A; Bhagat G; O'Connor OA
Hematol Oncol; 2020 Feb; 38(1):51-58. PubMed ID: 31872891
[TBL] [Abstract][Full Text] [Related]
29. Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.
Lansigan F; Horwitz SM; Pinter-Brown LC; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Shustov AR; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Park SI; Foss FM
Acta Haematol; 2020; 143(1):40-50. PubMed ID: 31315113
[TBL] [Abstract][Full Text] [Related]
30. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.
Armitage JO; Hsi ED; Foss FM
Clin Adv Hematol Oncol; 2010 Dec; 8(12 Suppl 22):1-15. PubMed ID: 21491667
[TBL] [Abstract][Full Text] [Related]
31. Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice.
O'Connor OA; Bhagat G; Ganapathi K; Pedersen MB; D'Amore F; Radeski D; Bates SE
Clin Cancer Res; 2014 Oct; 20(20):5240-54. PubMed ID: 25320373
[TBL] [Abstract][Full Text] [Related]
32. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.
Kim JG; Sohn SK; Chae YS; Cho YY; Yang DH; Lee JJ; Kim HJ; Shin HJ; Chung JS; Cho GJ; Lee WS; Joo YD; Sohn CH; Oh SJ
Cancer Chemother Pharmacol; 2007 Jun; 60(1):129-34. PubMed ID: 17406867
[TBL] [Abstract][Full Text] [Related]
33. The role of alisertib in treatment of peripheral T-cell lymphomas.
Gallop-Evans E
Future Oncol; 2015 Sep; 11(18):2515-24. PubMed ID: 26344156
[TBL] [Abstract][Full Text] [Related]
34. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Rashidi A; Cashen AF
Future Oncol; 2015; 11(11):1659-64. PubMed ID: 26043217
[TBL] [Abstract][Full Text] [Related]
35. Novel therapies in peripheral T-cell lymphomas.
O'Leary HM; Savage KJ
Curr Hematol Malig Rep; 2008 Oct; 3(4):213-20. PubMed ID: 20425468
[TBL] [Abstract][Full Text] [Related]
36. Peripheral T-cell lymphoma--not otherwise specified.
Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
[TBL] [Abstract][Full Text] [Related]
37. Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
Tomita N; Motomura S; Hyo R; Takasaki H; Takemura S; Taguchi J; Fujisawa S; Ogawa K; Ishigatsubo Y; Takeuchi K
Cancer; 2007 Mar; 109(6):1146-51. PubMed ID: 17311304
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
[TBL] [Abstract][Full Text] [Related]
39. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
Shustov A
Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
[TBL] [Abstract][Full Text] [Related]
40. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies.
Karlin L; Coiffier B
Semin Hematol; 2014 Jan; 51(1):25-34. PubMed ID: 24468313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
